A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

Inclusion Criteria: * Histologically documented locally advanced or metastatic solid tumor that has progressed or failed to respond to at least one prior regimen. * Not a candidate for regimens known to provide clinical benefit. * Evaluable or measurable disease according to RECIST, v1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening. * Life expectancy of \>= 12 weeks. * Adequate haematologic and organ function within 14 days prior to initiation of study treatment. * Women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating eggs. * Men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm. * Participants must reside in the People's Republic of China Exclusion Criteria: * Leptomeningeal disease as the only manifestation of the current tumor. * Type 1 or 2 diabetes mellitus requiring insulin at study entry. * Inability or unwillingness to swallow pills. * Malabsorption syndrome or other condition that would interfere with enteral absorption. * Known and untreated, or active CNS metastases (progressing or requiring anticonvulsants for symptomatic control). * Congenital long QT syndrome or corrected QT interval (QTc) \> 480 ms. * Active congestive heart failure or ventricular arrhythmia requiring medication. * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring weekly paracentesis for 3 consecutive weeks prior to initiation of ipatasertib treatment. * Severe infections within 4 weeks prior to screening including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. * Requirement for any daily supplemental oxygen. * History of Inflammatory bowel disease or active bowel inflammation. * Symptomatic hypercalcemia requiring continued use of bisphosphonate or denosumab therapy. * Clinically significant history of liver disease, including viral disease or hepatitis,current alcohol abuse or cirrhosis. * Known HIV infection. * Active (chronic or acute) hepatitis C virus (HCV) at screening. * Hepatitis B virus (HBV) infection (chronic or acute), defined as having a positive hepatitis B surface antigen (HBsAg) test or a positive quantitative HBV DNA test at screening * Significant traumatic injury within 3 weeks prior to initiation of ipatasertib treatment. * Major surgical procedure within 4 weeks prior to initiation of ipatasertib treatment. * Treatment with chemotherapy, immunotherapy, or biologic therapy as cancer therapy within 3 weeks prior to initiation of ipatasertib treatment. * Use of strong CYP3A4 inhibitors within 4 weeks prior to initiation of ipatasertib treatment. * Oral endocrine therapy within 2 weeks prior to initiation of ipatasertib treatment. * Prior treatment with a PI3-kinase inhibitor in which the patient experienced a Grade \>= 3 drug-related adverse event or otherwise would be at increased risk for additional PI3K-related toxicity. * Palliative radiation to bony metastases within 2 weeks prior to initiation of ipatasertib treatment. * Radiotherapy (other than palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of ipatasertib treatment. * Treatment with an investigational agent within 4 weeks prior to initiation of ipatasertib treatment. * Unresolved toxicity from prior therapy, except for alopecia and Grade 1 peripheral neuropathy. * Pregnant or lactating. * Inability to comply with study and follow-up procedures.